Rafferty Asset Management
VKTX icon

Rafferty Asset Management’s Viking Therapeutics VKTX Stock Holding History

Rafferty Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.88M Sell
99,475
-26,657
-21% -$861K 0.01% 424
2026
Q1 		$4.1M Sell
126,132
-28,875
-19% -$928K 0.02% 455
2025
Q4 		$5.45M Sell
155,007
-44,380
-22% -$1.57M 0.02% 411
2025
Q3 		$5.24M Buy
199,387
+41,888
+27% +$1.25M 0.02% 413
2025
Q2 		$4.17M Sell
157,499
-26,270
-14% -$692K 0.01% 431
2025
Q1 		$4.44M Sell
183,769
-87,394
-32% -$2.76M 0.02% 394
2024
Q4 		$10.9M Buy
271,163
+17,410
+7% +$993K 0.04% 272
2024
Q3 		$16.1M Sell
253,753
-81,813
-24% -$4.8M 0.06% 188
2024
Q2 		$17.8M Buy
335,566
+207,810
+163% +$13.6M 0.07% 165
2024
Q1 		$10.5M Sell
127,756
-285,522
-69% -$12.7M 0.04% 256
2023
Q4 		$7.69M Sell
413,278
-146,902
-26% -$1.92M 0.03% 341
2023
Q3 		$6.2M Buy
560,180
+217,827
+64% +$3.12M 0.04% 343
2023
Q2 		$5.55M Sell
342,353
-197,959
-37% -$4.15M 0.03% 387
2023
Q1 		$9M Buy
+540,312
New +$5.58M 0.06% 206
2022
Q1 		– Sell
-229,119
Closed -$1.05M – 1327
2021
Q4 		$1.05M Buy
229,119
+97,715
+74% +$548K 0.01% 840
2021
Q3 		$825K Sell
131,404
-54,032
-29% -$334K 0.01% 914
2021
Q2 		$1.11M Sell
185,436
-162,534
-47% -$965K 0.01% 841
2021
Q1 		$2.2M Buy
347,970
+291,934
+521% +$2.05M 0.02% 595
2020
Q4 		$315K Sell
56,036
-96,604
-63% -$585K ﹤0.01% 797
2020
Q3 		$888K Buy
152,640
+100,155
+191% +$690K 0.01% 591
2020
Q2 		$378K Buy
52,485
+38,152
+266% +$253K 0.01% 778
2020
Q1 		$67K Sell
14,333
-107,414
-88% -$660K ﹤0.01% 570
2019
Q4 		$976K Sell
121,747
-135,293
-53% -$986K 0.02% 557
2019
Q3 		$1.77M Sell
257,040
-226,052
-47% -$1.68M 0.03% 423
2019
Q2 		$4.01M Buy
483,092
+37,523
+8% +$321K 0.07% 213
2019
Q1 		$4.43M Buy
+445,569
New +$3.73M 0.07% 158

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rafferty Asset Management's VKTX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Viking Therapeutics (VKTX) stake by 21% in Q2 2026, selling an estimated $861K and leaving 99,475 shares worth $3.88M. The position accounts for 0.01% of the portfolio, ranked #424.

Rafferty Asset Management first reported a position in VKTX in Q1 2019 and has held it in 26 quarters since. The position peaked at $17.8M in Q2 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Rafferty Asset Management held 99,475 shares of Viking Therapeutics worth $3.88M as of Q2 2026.
  • Rafferty Asset Management sold 26,657 Viking Therapeutics shares in Q2 2026, an estimated $861K.
  • Viking Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #424 holding.
  • Rafferty Asset Management first reported a position in Viking Therapeutics in Q1 2019 and has held it in 26 quarters since.
  • Rafferty Asset Management's Viking Therapeutics position peaked at $17.8M in Q2 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.